Logo

OpiCalc

FavoritesSpecialtiesDrugsGuidelinesMost Used

Quick Access

Favorites
Most Used

All Specialties

OpiCalc Logo
Clinical CalculatorsDrugsGuidelines
SpecsDrugsGuides
ABC-AF Bleeding ScoreABC-AF Stroke ScoreABCD2 ScoreADD-RSAortic Valve Calcium ScoreAPPLE ScoreASCVD (Pooled Cohort)AVA (Continuity Equation)BAG-AHF ScoreBiplane Simpson EFBlood Pressure PercentilesBrugada Criteria (VT vs SVT)Cardiac Output IndexCHA2DS2-VAScCHADS2Cornell Voltage CriteriaCRUSADE Bleeding ScoreDAPT ScoreDASIDuke Treadmill ScoreE/A RatioEDACS ScoreEHMRGEHRA ScoreEmbolic Risk ScoreEROA (PISA Method)FFR (Fractional Flow Reserve)Fick Cardiac OutputFramingham 10-Year RiskFriedewald LDL EquationGorlin EquationGRACE ScoreGupta MICA (NSQIP)GWTG-HF ScoreH2FPEF ScoreHakki FormulaHAS-BLEDHEART PathwayHEART ScoreHEMORR2HAGEShs-Troponin 0h/1h ESC AlgorithmiFRINTERCHEST ScoreKillip ClassificationLee's RCRILV Mass IndexLV Stroke Work IndexMAGGIC Risk ScoreMAP CalculatorMartin/Hopkins LDLModified Duke CriteriaModified Sgarbossa CriteriaMVA (Pressure Half-Time)Non-HDL CholesterolNT-proBNP Age-Adjusted ThresholdsORBIT ScoreOttawa Heart Failure RiskPREVENT EquationsPulse PressurePVR CalculatorPVR IndexQRISK3QTc (Bazett)QTc (Fridericia)REVEAL 2.0 ScoreREVEAL Lite 2Reynolds Risk ScoreROSIRVSP CalculatorSchwartz Score (LQTS)SCORE2Seattle Heart Failure Model (SHFM)Sgarbossa CriteriaShock IndexSokolow-Lyon VoltageStroke Volume IndexSVR CalculatorSYNTAX ScoreSYNTAX Score IITAPSETeichholz FormulaTIMI (STEMI)TIMI (UA/NSTEMI)Troponin Delta CalculatorValvular GradientsVancouver Chest Pain RuleVereckei AlgorithmWATCHDM ScoreWilkins ScoreWood Units Calculator
OpiCalc Logo

OpiCalc

Easy, fast, and private medical tools for clinicians. Always free.

No Login Required
Ready for the Bedside

Resources

About UsEditorial PolicyMedical DisclaimerPrivacy PolicyTerms of UseCookie Policy

Support

Contact Us

Clinical Notice:OpiCalc is not a substitute for professional clinical judgment. Always verify dosages and guidelines.

OpiCalc © 2026

•

All Rights Reserved

ABC-AF Stroke Score

ABC-AF Stroke Score: Age + Biomarkers (NT-proBNP, hsTnT) + Clinical history for AF stroke risk (ESC 2020).

Prior Stroke or TIA
Vascular Disease (CAD, PAD, Stroke)
Guidelines & Evidence

Verified

Last Review: 2026-07-17

When to Use

When to Use

Prognostication of stroke or systemic embolism (SE) in patients with Atrial Fibrillation (AF).
Identification of low-risk patients who may not require oral anticoagulation (OAC).
Refining risk assessment in patients categorized as "intermediate risk" by clinical-only scores.
Endorsed by ESC 2020/2024 guidelines as a preferred tool when biomarkers are available.

Patient Population

Derived from the ARISTOTLE trial (n = 14,701) and externally validated in the STABILITY trial (n = 1,400) and LOOP study (n = 5,781). Includes patients with paroxysmal, persistent, or permanent AF.

When Not to Use

When high-sensitivity troponin or NT-proBNP assays are unavailable.
Valvular AF (mechanical valves/moderate-severe mitral stenosis).
Acute stroke or SE triage — this is a long-term risk stratification tool.

How it Works

Input Variables (ABC)

A — AgeContinuous variable (years)
B — BiomarkersNT-proBNP (ng/L) and hs-cTn (T or I)
C — Clinical HistoryPrior Stroke or Transient Ischaemic Attack (TIA)

Biomarker Rationale

01
NT-proBNP: A sensitive indicator of atrial and ventricular wall stress and myocyte strain.
02
hs-cTn (High-Sensitivity Troponin): Reflects subclinical myocardial injury and vascular vulnerability.

Risk Stratification

Low Risk< 1% 1-year risk
Medium Risk1% – 2% 1-year risk
High Risk> 2% 1-year risk

Clinical Pearls

Predictive Superiority

The ABC-AF Stroke score consistently outperforms clinical-only scores. In derivation cohorts, it achieved a C-index of 0.68 vs. 0.62 for CHA2DS2-VASc (P < 0.001). This superiority is maintained even in primary prevention (patients with no prior stroke).

Insights from the LOOP Study (2024)

In AF-naïve elderly populations, a higher ABC-stroke score identifies those at higher risk of incident AF and cardioembolic stroke, but it did not identify a subgroup that specifically benefited from ILR-based screening in terms of overall stroke reduction.

Clinical Pearls

Biomarkers capture subclinical cardiovascular dysfunction better than simple diagnosis "labels" (e.g., "Heart Failure").
Dynamic nature: Unlike clinical scores, biomarker levels can fluctuate, reflecting a change in the patient's actual physiological risk over time.
In patients with borderline CHA2DS2-VASc scores, the ABC score can clarify the net benefit of starting OAC.

Next Steps

Management Considerations

01
Score < 1%/year: Truly low-risk population; consider if the risks of anticoagulation (bleeding) outweigh the minimal stroke prevention benefit.
02
Score 1–2%/year: Moderate risk; anticoagulation is generally indicated, especially if CHA2DS2-VASc is ≥ 2.
03
Score > 2%/year: High risk; anticoagulation is strongly favored. The absolute benefit of OAC (e.g., Apixaban vs. Warfarin) is most pronounced in this group.

The Evidence

Original Derivation & Validation

The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation.

Hijazi Z et al. • European Heart Journal. 2016;37(20):1582–1590. Landmark study establishing biomarker superiority over clinical-only scores (C-index 0.68 vs 0.62).

View Source

Validation in AF-Naïve (LOOP Study)

The ABC-Stroke Risk Score and Effects of Atrial Fibrillation Screening on Stroke Prevention: Results From the Randomized LOOP Study.

Xing LY et al. • Journal of the American Heart Association. 2024;13(4):e032744. Evaluated the score in high-risk individuals without known AF, confirming stroke prediction utility but limited screening stratification value.

View Source

Click to Read

Origins & History

Uppsala Clinical Research Center

The ABC-AF framework was developed by Ziad Hijazi and colleagues at the Uppsala Clinical Research Center (Sweden). It moved stroke prevention away from categorical "yes/no" diagnoses toward a continuous physiological model based on myocyte stress and injury.

TRIPOD Adherence

The development and validation were conducted in strict adherence to the TRIPOD statement for multivariable prediction models, ensuring high-quality evidence for implementation in clinical care.

Last Comprehensive Review: 2026-07-17

Recent Journal Updates

WHO NewsJul 2, 2026
WHO adds first diagnostic test for Ebola Bundibugyo virus to its Emergency Use Listing

Clinical Context

We think this has broad domain relevance to ABCAF Stroke Score.

BJOGJun 25, 2026
Indications and Efficacy of Progestogen‐Monotherapy as Menopause Hormone Therapy: A Narrative Review

Clinical Context

We think this has broad domain relevance to ABCAF Stroke Score.